Zogenix Provides Update on Zohydro(TM) ER NDA
If approved, Zohydro ER will be classified as a
If approved, Zohydro ER is expected to be the first extended-release formulation hydrocodone therapy without acetaminophen. The use of products containing acetaminophen in high doses over long periods of time has the potential for causing liver injury. Acetaminophen overdose is a leading cause of acute liver failure in
SUMAVEL®, DosePro®, ReldayTM and ZohydroTM ER are trademarks of
SODAS® is a trademark of
[i] Michna, E, Duh, MS, Korves, C, Dahl, JL. Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Medicine. 2010; 11: 369-378.
Zack Kubow| The Ruth Group646.536.7020 | email@example.com Media Julie Normart| WCG 415.946.1087 | firstname.lastname@example.org